艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABBV 艾伯维公司

交易中 04-24 14:10:31 EDT

168.36

-1.18

-0.70%

最高169.11	最低166.74	成交量142.40万
今开168.36	昨收169.54	日振幅1.40%
总市值2,981亿	流通市值2,974亿	总股本17.71亿
成交额2.40亿	换手率0.08%	流通股本17.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":168.355,"timestamp":1713982228682,"preClose":169.54,"halted":0,"volume":1424044,"delay":0,"floatShares":1766775109,"shares":1770646983,"eps":2.72,"marketStatus":"交易中","marketStatusCode":2,"change":-1.185,"latestTime":"04-24 14:10:31 EDT","open":168.355,"high":169.11,"low":166.74,"amount":239579596.1116,"amplitude":0.013979,"askPrice":168.38,"askSize":25,"bidPrice":168.33,"bidSize":11,"shortable":3,"etf":0,"ttmEps":2.72,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713988800000},"adr":0,"adjPreClose":169.54,"adrRate":0,"dividendRate":0.03558,"preHourTrading":{"tag":"盘前","latestPrice":168.43,"preClose":169.54,"latestTime":"09:29 EDT","volume":732,"amount":124023.38952,"timestamp":1713965399091},"postHourTrading":{"tag":"盘后","latestPrice":169.55,"preClose":169.54,"latestTime":"19:17 EDT","volume":154858,"amount":26254339.82,"timestamp":1713914260637},"volumeRatio":0.40385},"requestUrl":"/m/hq/s/ABBV/tweets","defaultTab":"tweets","newsList":[{"id":"2429458989","title":"艾伯维公司  预计每股收益2.23美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429458989","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429458989?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:32","pubTimestamp":1713961964,"startTime":"0","endTime":"0","summary":"   * 艾伯维公司   将于4月26日公布截至2024年3月31日的季度业绩报告，预计该公司的季度收入将出现下降。   * LSEG 的分析师平均预期艾伯维公司的每股收益为 2.23 美元。该公司 2024 年 2 月 12 日发布的截至 3 月 31 日的每股收益指导值介于 2.26 和 2.30 之间。* 华尔街对艾伯维公司 12 个月目标价的中位数为 189.39 美元，高于其上次收盘价 169.54 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429129331","title":"美国疾控中心警告注射假肉毒杆菌会产生有害反应","url":"https://stock-news.laohu8.com/highlight/detail?id=2429129331","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429129331?lang=zh_cn&edition=full","pubTime":"2024-04-24 00:14","pubTimestamp":1713888884,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月23日 - 美国疾病控制和预防中心(CDC) 周二提醒临床医生注意艾伯维公司  的假冒肉毒杆菌毒素在多个州被用于美容目的的风险。美国疾病预防控制中心、美国食品和药物管理局(FDA) 以及州和地方合作伙伴正在调查关于注射了假冒肉毒杆菌毒素的人出现有害反应的报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429157440","title":"专利到期 仿制药大卖导致艾伯维营收减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2429157440","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2429157440?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:24","pubTimestamp":1713857042,"startTime":"0","endTime":"0","summary":"拥有药王“修美乐”的生物制药企业艾伯维即将公布财报，但股价连番下跌，如何看待这个企业？文章来源：第一财经原标题：专利到期 仿制药大卖导致艾伯维营收减少","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042315455687a510a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042315455687a510a8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429139311","title":"一药治三病！辉瑞(PFE.US)&艾伯维(ABBV.US)小分子疗法获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2429139311","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429139311?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:25","pubTimestamp":1713842723,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，辉瑞宣布，欧盟委员会批准其与艾伯维联合开发的Emblaveo上市，用于治疗成人复杂性腹腔内感染、医院获得性肺炎，以及复杂性尿路感染。根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。Emblaveo是aztreonam和avibactam这两种抗生素的组合。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107359.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427873062","title":"更新版 1-美国 FDA 就假冒肉毒杆菌毒素注射剂的有害反应发出警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2427873062","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427873062?lang=zh_cn&edition=full","pubTime":"2024-04-16 22:21","pubTimestamp":1713277300,"startTime":"0","endTime":"0","summary":"美国疾病控制和预防中心 和美国食品和药物管理局正在调查关于注射了假冒肉毒杆菌毒素的人出现有害反应的报告。美国食品和药物管理局的调查仍在进行中，该机构目前正与肉毒杆菌制造商艾伯维公司合作，查明并清除在美国发现的疑似假冒肉毒杆菌产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2425998180","title":"（投资中国）艾伯维全球高级副总裁：将继续加大对华投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2425998180","media":"中国新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2425998180?lang=zh_cn&edition=full","pubTime":"2024-04-08 19:38","pubTimestamp":1712576304,"startTime":"0","endTime":"0","summary":"艾伯维全球高级副总裁、国际治疗领域总裁艾尔贝托·科尔奇近日接受中新社记者采访时称，中国是该公司最重要的市场之一，今后将继续加大对中国市场的投入。中国对艾伯维的吸引力主要来自其庞大的市场规模。中国进一步扩大开放、改善营商环境也使艾伯维愿意继续投资中国。得益于中国新药注册审评制度的持续优化，艾伯维创新药在中国的获批能够与全球市场同步，这使其对在华发展充满信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081939078afe66d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081939078afe66d0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425320311","title":"Humira生物仿制药销售滞后，勃林格将裁减销售人员","url":"https://stock-news.laohu8.com/highlight/detail?id=2425320311","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2425320311?lang=zh_cn&edition=full","pubTime":"2024-04-05 06:50","pubTimestamp":1712271031,"startTime":"0","endTime":"0","summary":" Patrick  Wingrove    路透社4月4日 - 勃林格殷格翰公司周四表示，由于艾伯维公司  的关节炎治疗大片Humira在美国的生物仿制药销售不佳，该公司将裁减部分销售人员。该公司表示，这种选择导致美国对Humira的生物仿制药的使用率降低。同期，Humira的处方量接近280万张。勃林格公司的Humira生物仿制药是第一个被美国食品和药物管理局指定为可互换的药物，这意味着它可以在不咨询处方医生的情况下替代原研药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422179635","title":"BUZZ-受艾伯维收购交易影响，兰多斯生物制药公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2422179635","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422179635?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:24","pubTimestamp":1711373062,"startTime":"0","endTime":"0","summary":"    3月25日 - ** 疗法开发商兰多斯生物制药公司  的股价盘前上涨两倍多，达到23.56美元 ** 艾伯维  将以最高2.12亿美元的价格收购该公司  ** 根据交易，ABBV将以每股20.42美元的现金收购Landos，总价约为1.375亿美元，比LABP上周五收盘价溢价160.8%。** ABBV还将向Landos股东支付每股最多11.14美元的额外里程碑付款，总额约为7500万美元。** 截至上一交易日收盘，LABP 的股价比去年同期翻了一番多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422514079","title":"更新版 1-艾伯维通过兰多斯交易加强免疫疾病药物管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2422514079","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422514079?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:03","pubTimestamp":1711371806,"startTime":"0","endTime":"0","summary":"艾伯维的大片药物 Rinvoq 已被批准用于治疗这种疾病，同时该公司还在寻求美国食品药品管理局批准其另一种主要药物 Skyrizi。根据这项交易，艾伯维将以每股 20.42 美元的现金收购兰多斯，总价约为 1.375 亿美元。在短暂停牌后，兰多斯的股价在收盘前飙升至 22.13 美元。两家公司表示，交易预计将在第二季度完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422519043","title":"艾伯维将收购兰多斯，扩大免疫相关疾病的产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2422519043","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422519043?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:37","pubTimestamp":1711370251,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月25日 - 艾伯维  周一表示，将以不超过2.12亿美元的价格收购药物开发商兰多斯生物制药  ，这家Humira生产商的目标是扩大其治疗免疫系统相关疾病的药物产品线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422249595","title":"华东医药：ELAHERE®（索米妥昔单抗注射液）获美国FDA完全批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2422249595","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422249595?lang=zh_cn&edition=full","pubTime":"2024-03-25 17:23","pubTimestamp":1711358621,"startTime":"0","endTime":"0","summary":"3月25日，华东医药公告称，公司全资子公司杭州中美华东制药有限公司（简称“中美华东”）美国合作方AbbVieInc.（简称“AbbVie”）对外宣布，其用于治疗铂耐药卵巢癌的ADC药物ELAHERE®（索米妥昔单抗注射液）获得美国食品药品监督管理局（FDA）完全批准。公告显示，ELAHERE®为中美华东与ImmunoGen,Inc.（目前已被AbbVie收购）合作开发的针对叶酸受体α靶点的ADC药物，由FRα结合抗体、可裂解的连接子和美登木素生物碱DM4组成。中美华东拥有该产品在大中华区（含中国大陆、香港、澳门和台湾地区）的独家临床开发及商业化权益。（深交所）(编辑：周彤)关键字：","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325172405791c9a17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325172405791c9a17&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421825550","title":"美国 FDA 全面批准艾伯维的卵巢癌疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2421825550","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421825550?lang=zh_cn&edition=full","pubTime":"2024-03-23 02:35","pubTimestamp":1711132528,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月22日 - 美国食品和药物管理局(FDA) 美国食品和药物管理局周五表示，它已批准艾伯维公司  的 \"制导导弹 \"癌症疗法Elahere用于治疗一种卵巢癌和相关癌症的成年患者，这些患者此前已接受过一至三种治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419983375","title":"BUZZ-穆迪称因GLP-1药物推动制药业前景转为 \"积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2419983375","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419983375?lang=zh_cn&edition=full","pubTime":"2024-03-14 22:35","pubTimestamp":1710426957,"startTime":"0","endTime":"0","summary":"    3月14日 - ** 穆迪评级公司称，GLP-1 和其他大片药物已将美国制药业信贷展望从 \"稳定 \"提升至 \"积极\"。** 评级机构表示，该行业的增长将受益于大片药物使用量的增加，包括诺和诺德  和礼来  的GLP-1糖尿病和减肥治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2415677015","title":"艾伯维肺癌数据照亮ADC加速审批之路，但未达到早期基准","url":"https://stock-news.laohu8.com/highlight/detail?id=2415677015","media":"亿欧网","top":-1,"share":"https://www.laohu8.com/m/news/2415677015?lang=zh_cn&edition=full","pubTime":"2024-02-29 15:05","pubTimestamp":1709190345,"startTime":"0","endTime":"0","summary":"AbbVie旨在加速批准其用于肺癌患者的c-Met抗体-药物偶联物（ADC），telisotuzumab vedotin（Teliso-V）。在光度试验中，Teliso-V在高c-Met表达的患者中显示出35%的缓解率，在中等表达的患者中显示出23%的缓解率。尽管这些比率低于早期数据，但AbbVie报告称总体生存率中位数有所提高，并计划与监管机构讨论加速批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022915171187d090ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022915171187d090ca&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413234890","title":"制药巨头艾伯维拟出售130亿美元债券，为并购作准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2413234890","media":"金十数据","top":-1,"share":"https://www.laohu8.com/m/news/2413234890?lang=zh_cn&edition=full","pubTime":"2024-02-22 11:29","pubTimestamp":1708572585,"startTime":"0","endTime":"0","summary":"去年年底，这家制药巨头同意收购ImmunoGen、Cerevel两家公司。","market":"us","thumbnail":"https://static.tigerbbs.com/202d5f7a31e9e8725ee64c650896759f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/202d5f7a31e9e8725ee64c650896759f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=132798&type=news&data_type=0","is_publish_highlight":true,"gpt_icon":1},{"id":"2413385822","title":"传艾伯维(ABBV.US)拟出售至少130亿美元债券为并购融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2413385822","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2413385822?lang=zh_cn&edition=full","pubTime":"2024-02-22 09:51","pubTimestamp":1708566696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，艾伯维正寻求出售至少130亿美元的公司债券，为其收购ImmunoGen和Cerevel Therapeutics提供资金。此次发行的规模可能会有所变化，并将在发行当天确定。艾伯维没有立即回应置评请求。据悉，去年12月，艾伯维接连宣布了两项收购——以87亿美元收购Cerevel的计划，以及最近完成的以101亿美元收购ImmunoGen的交易。此后，艾伯维表示，计划将重点放在规模较小的交易上，以支持其在未来十年的增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022209545281a631c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022209545281a631c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413288928","title":"据彭博社报道，艾伯维希望出售至少 130 亿美元债券为并购提供资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2413288928","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413288928?lang=zh_cn&edition=full","pubTime":"2024-02-22 07:03","pubTimestamp":1708556582,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社2月21日 - 彭博新闻社周三援引知情人士的话报道，艾伯维  正寻求出售至少130亿美元的公司债券，以帮助其为收购ImmunoGen和Cerevel Therapeutics  提供资金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":0.0431},{"period":"1month","weight":-0.0499},{"period":"3month","weight":0.0324},{"period":"6month","weight":0.1676},{"period":"1year","weight":0.0333},{"period":"ytd","weight":0.094}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":-0.0299},{"period":"3month","weight":0.0417},{"period":"6month","weight":0.2257},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.023334},{"month":2,"riseRate":0.833333,"avgChangeRate":0.030818},{"month":3,"riseRate":0.75,"avgChangeRate":0.006329},{"month":4,"riseRate":0.666667,"avgChangeRate":0.018882},{"month":5,"riseRate":0.727273,"avgChangeRate":0.007528},{"month":6,"riseRate":0.454545,"avgChangeRate":0.004829},{"month":7,"riseRate":0.454545,"avgChangeRate":0.00558},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.006918},{"month":9,"riseRate":0.454545,"avgChangeRate":0.007981},{"month":10,"riseRate":0.636364,"avgChangeRate":0.011149},{"month":11,"riseRate":0.818182,"avgChangeRate":0.080758},{"month":12,"riseRate":0.727273,"avgChangeRate":0.032678}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况